About
Cytokine Immunotherapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
177
By Phase
PHASE1: 3
By Status
RECRUITING: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07100925Lead Sponsor
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
PHASE1Not yet recruiting
20 participants
Started: Dec 15, 2025 · Completed: Dec 31, 2030
NCT07027514Lead Sponsor
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
PHASE1Recruiting
60 participants
Started: Sep 30, 2025 · Completed: Dec 31, 2028
NCT06171750Lead Sponsor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
PHASE1Recruiting
97 participants
Started: Jan 19, 2024 · Completed: Jun 30, 2027
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...